Not investment advice. Origin reports data from public SEC filings with cryptographic provenance. No buy/sell/hold recommendations. Past performance does not indicate future results.
## CEL-SCI Corp at $1.48: Incremental Query Accumulation Confirms Latent Interest Amid Continued Information Vacuum
Two days after initiating coverage at $1.42, CVM has ticked up to $1.48 — a modest 4.2% move with no identifiable catalyst visible in the filing or transcript data. The AI query count on Origin has grown from 222 to 226, a net addition of 4 queries in roughly 48 hours. This slow, steady accumulation rather than a spike pattern suggests ambient monitoring activity rather than event-driven research — consistent with a small cohort watching for a clinical or regulatory catalyst that has not yet materialized. Zero earnings transcripts remain captured, leaving the information architecture unchanged from the inaugural observation. The filing signal structure warrants a closer structural note this observation. The 10-K data now surfaces a cleaner breakdown: the risk_factor category shows three distinct cluster readings at 22, 8, and 7 matches respectively, while ai_adoption splits across two clusters at 8 and 4 matches. The strategic_event category shows three clusters at 6, 6, and 5 matches. This cluster distribution suggests the 10-K contains multiple discrete sections generating these signals rather than a single concentrated disclosure block — consistent with a document organized around distinct risk domains, likely separating clinical, financial, and operational risk language into separate sections. Watch for: any query volume spike above 10 per day, which would suggest an information event has reached retail awareness before appearing in captured filings; the first transcript capture on Origin, which remains the single highest-value data unlock for this coverage; and any SEC filing activity that resolves which strategic-event cluster is driving the highest match density.
## CEL-SCI Corp at $1.42: Initiating Coverage on a Late-Stage Immunology Binary Event Story
This is the inaugural observation for CEL-SCI Corp (CVM), a clinical-stage biopharmaceutical company trading at $1.42 with a sub-$1B market capitalization as of August 21, 2026. With 222 all-time AI queries on Origin and zero earnings transcripts captured, the information architecture around CVM is sparse — a meaningful signal in itself. The filing-level analysis from the latest 10-K reveals a heavily risk-weighted document: 22 distinct risk-factor matches dominate the signal landscape, alongside 8 ai_adoption matches and at least 17 strategic-event matches across multiple clusters. This pattern — high risk disclosure, moderate strategic signaling, and emerging AI-adjacent language — is consistent with a company navigating late-stage clinical uncertainty while attempting to articulate a forward technology narrative. The concentration of risk-factor language in the 10-K warrants close reading. For a company at this price point and capitalization, binary clinical outcomes likely drive the bulk of that disclosure density. The presence of 8 ai_adoption matches is worth tracking — whether this reflects genuine platform integration or regulatory/competitive boilerplate will become clearer as transcript data accumulates. Watch for: any Phase 3 readout or IND-related filing updates that would crystallize the risk-factor disclosures into concrete catalysts; the first earnings transcript capture on Origin, which will allow sentiment and management tone analysis; and whether the ai_adoption language in filings begins correlating with operational announcements. The 222 query volume suggests retail or algorithmic interest exists — context for that interest remains undefined.